Adverse events during immunotherapy in Slovenian patients with metastatic melanoma reveal a positive correlation with better treatment outcomes

1Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski R, Lao CD, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 2019; 381: 1535-46. doi: 10.1056/NEJMoa1910836Larkin J Chiarion-Sileni V Gonzalez R Grob JJ Rutkowski R Lao CD et al Five-year survival with combined nivolumab and ipilimumab in advanced melanoma N Engl J Med 2019 381 1535 46 10.1056/NEJMoa191083631562797Open DOISearch in Google Scholar

2Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol 2019; 30: 582-8. doi: 10.1093/annonc/mdz011Hamid O Robert C Daud A Hodi FS Hwu WJ Kefford R et al Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001 Ann Oncol 2019 30 582 8 10.1093/annonc/mdz011650362230715153Open DOISearch in Google Scholar

3Robert C, Hwu W-J, Hamid O, Ribas A, Weber JS, Daud AI, et al. Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: a landmark analysis in patients with advanced melanoma. Eur J Cancer 2021; 144: 182-91. doi: 10.1016/j.ejca.2020.11.010Robert C Hwu W-J Hamid O Ribas A Weber JS Daud AI et al Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: a landmark analysis in patients with advanced melanoma Eur J Cancer 2021 144 182 91 10.1016/j.ejca.2020.11.010838812833360855Open DOISearch in Google Scholar

4Hocevar M, Strojan P, Ocvirk J, Peric B, Blatnik O, Luzar B, et al. [Recommendation for the treatment of patients with melanoma]. [Slovenian]. Rebersek M, editor. [cited 2020 Oct 15]. Ljubljana: Institute of Oncology Ljubljana; 2019. Available at: https://www.onko-i.si/fileadmin/onko/datoteke/Strokovna_knjiznica/smernice/Priporocila_za_obravnavo_bolnikov_z_melanomom_2020.pdfHocevar M Strojan P Ocvirk J Peric B Blatnik O Luzar B et al [Recommendation for the treatment of patients with melanoma]. [Slovenian]. Rebersek M, editor. [cited 2020 Oct 15] Ljubljana Institute of Oncology Ljubljana 2019 Available at https://www.onko-i.si/fileadmin/onko/datoteke/Strokovna_knjiznica/smernice/Priporocila_za_obravnavo_bolnikov_z_melanomom_2020.pdfSearch in Google Scholar

5Michielin O, van Akkooi ACJ, Ascierto PA, Dummer R, Keilholz U, on behalf of the ESMO Guidelines Committee. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2019; 30: 1884-901. doi: 10.1093/annonc/mdz411Michielin O van Akkooi ACJ Ascierto PA Dummer R Keilholz U on behalf of the ESMO Guidelines Committee. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 2019 30 1884 901 10.1093/annonc/mdz41131566661Open DOISearch in Google Scholar

6NCCN Clinical Practice Guidelines in Oncology, Cutaneous melanoma. Version 4.2020. [cited 2020 Oct 14]. Available at: https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdfNCCN Clinical Practice Guidelines in Oncology, Cutaneous melanoma Version 4.2020. [cited 2020 Oct 14]. Available at https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdfSearch in Google Scholar

7Bisschop C, Wind TT, Blank CU, Koornstra RHT, Kapiteijn E, Van den Eertwegh AJM, et al. Association between pembrolizumab-related adverse events and treatment outcome in advanced melanoma: results from the Dutch Expanded Access Program. J Immunother 2019; 42: 208-14. doi: 10.1097/CJI.0000000000000271Bisschop C Wind TT Blank CU Koornstra RHT Kapiteijn E Van den Eertwegh AJM et al Association between pembrolizumab-related adverse events and treatment outcome in advanced melanoma: results from the Dutch Expanded Access Program J Immunother 2019 42 208 14 10.1097/CJI.000000000000027131145233Open DOISearch in Google Scholar

8Suo AE, Chan Y, Cheung WY, Monzon JG, Smylie M, Walker JWT, et al. Pembrolizumab-induced immune related adverse events and survival outcomes in advanced melanoma. [abstract]. J Clin Oncol 2018; 36 (15 Suppl): e21577. doi: 10.1200/JCO.2018.36.15_suppl.e21577Suo AE Chan Y Cheung WY Monzon JG Smylie M Walker JWT et al Pembrolizumab-induced immune related adverse events and survival outcomes in advanced melanoma [abstract]. J Clin Oncol 2018 36 15 Suppl e21577 10.1200/JCO.2018.36.15_suppl.e21577Open DOISearch in Google Scholar

9Hussaini S, Chehade R, Boldt RG, Raphael J, Blanchette P, Maleki Vareki S, et al. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - a systematic review and meta-analysis. Cancer Treat Rev 2021; 92: 102134. doi: 10.1016/j.ctrv.2020.102134Hussaini S Chehade R Boldt RG Raphael J Blanchette P Maleki Vareki S et al Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - a systematic review and meta-analysis Cancer Treat Rev 2021 92 102134 10.1016/j.ctrv.2020.10213433302134Open DOISearch in Google Scholar

10Nishijima TF, Shachar SS, Nyrop KA, Muss HB. Safety and tolerability of PD-1/PD-L1 inhibitors compared with chemotherapy in patients with advanced cancer: a meta-analysis. Oncologist 2017; 22: 470-9. doi: 10.1634/theoncologist.2016-0419Nishijima TF Shachar SS Nyrop KA Muss HB Safety and tolerability of PD-1/PD-L1 inhibitors compared with chemotherapy in patients with advanced cancer: a meta-analysis Oncologist 2017 22 470 9 10.1634/theoncologist.2016-0419538838128275115Open DOISearch in Google Scholar

11EMA. Annex I. Summary of product characteristics. Ipilimumab (Yervoy) product information. [cited 2020 Oct 13]. Available at: https://www.ema.europa.eu/en/documents/product-information/yervoy-epar-product-infor-mation_en.pdfEMA. Annex I. Summary of product characteristics. Ipilimumab (Yervoy) product information. [cited 2020 Oct 13] Available at https://www.ema.europa.eu/en/documents/product-information/yervoy-epar-product-infor-mation_en.pdfSearch in Google Scholar

12EMA. Annex I. Summary of product characteristics. Pembrolizumab (Keytruda) product information: [cited 2020 Oct 12]. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdfEMA. Annex I. Summary of product characteristics Pembrolizumab (Keytruda) product information: [cited 2020 Oct 12] https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdfSearch in Google Scholar

13EMA. Annex I. Summary of product characteristics. Nivolumab (Opdivo) product information: [cited 2020 Oct 11]. https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_sl.pdfMA. Annex I. Summary of product characteristics Nivolumab (Opdivo) product information: [cited 2020 Oct 11] https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_sl.pdfSearch in Google Scholar

14Hribernik N, Boc M, Ocvirk J, Knez-Arbeiter J, Mesti T, Ignjatovic M, et al. Retrospective analysis of treatment-naive Slovenian patients with metastatic melanoma treated with pembrolizumab – real-world experience. Radiol Oncol 2020; 54: 119-27. doi: 10.2478/raon-2020-0003Hribernik N Boc M Ocvirk J Knez-Arbeiter J Mesti T Ignjatovic M et al Retrospective analysis of treatment-naive Slovenian patients with metastatic melanoma treated with pembrolizumab – real-world experience Radiol Oncol 2020 54 119 27 10.2478/raon-2020-0003708741631955148Open DOISearch in Google Scholar

15Bystryn JC. Serum antibodies in vitiligo patients. Clin Dermatol 1989; 7: 136-45; doi: 10.1016/0738-081x(89)90063-1Bystryn JC Serum antibodies in vitiligo patients Clin Dermatol 1989 7 136 45 10.1016/0738-081x(89)90063-12667738Open DOISearch in Google Scholar

16Oyarbide-Valencia K, van den Boorn JG, Denman CJ, Li M, Carlson JM, Hernandez C, et al. Therapeutic implications of autoimmune vitiligo T cells. Autoimmun Rev 2006; 5: 486-92. doi: 10.1016/j.autrev.2006.03.012Oyarbide-Valencia K van den Boorn JG Denman CJ Li M Carlson JM Hernandez C et al Therapeutic implications of autoimmune vitiligo T cells Autoimmun Rev 2006 5 486 92 10.1016/j.autrev.2006.03.012346265616920575Open DOISearch in Google Scholar

17Hua C, Boussemart L, Mateus C, Routier E, Boutros C, Cazenave H, et al. Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. JAMA Dermatol 2016; 152: 45-51. doi: 10.1001/jamadermatol.2015.2707Hua C Boussemart L Mateus C Routier E Boutros C Cazenave H et al Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab JAMA Dermatol 2016 152 45 51 10.1001/jamadermatol.2015.270726501224Open DOISearch in Google Scholar

18Dick J, Lang N, Slynko A, Kopp-Schneider A, Schulz C, Dimitrakopoulou-Strauss A, et al. Use of LDH and autoimmune side effects to predict response to ipilimumab treatment. Immunotherapy 2016, 8: 1033-44. doi: 10.2217/imt-2016-0083Dick J Lang N Slynko A Kopp-Schneider A Schulz C Dimitrakopoulou-Strauss A et al Use of LDH and autoimmune side effects to predict response to ipilimumab treatment Immunotherapy 2016 8 1033 44 10.2217/imt-2016-008327485076Open DOISearch in Google Scholar

19Olson D, Luke JJ, Poklepovic AS, Bajaj M, Higgs E, Carll TC, et al. Significant antitumor activity for low-dose ipilimumab (IPI) with pembrolizumab (PEMBRO) immediately following progression on PD1 Ab in melanoma (MEL) in a phase II trial. [abstract]. J Clin Oncol 2020; 38 (Suppl 15): 10004. doi: 10.1200/JCO.2020.38.15_suppl.10004Olson D Luke JJ Poklepovic AS Bajaj M Higgs E Carll TC et al Significant antitumor activity for low-dose ipilimumab (IPI) with pembrolizumab (PEMBRO) immediately following progression on PD1 Ab in melanoma (MEL) in a phase II trial [abstract]. J Clin Oncol 2020 38 Suppl 15 10004 10.1200/JCO.2020.38.15_suppl.10004Open DOISearch in Google Scholar

20Kluger HM, Chiang V, Mahajan A, Zito CR, Sznol M, Tran T, et al. Long-term survival of patients with melanoma with active brain metastases treated with pembrolizumab on a phase II trial. J Clin Oncol 2019; 37: 52-60. doi: 10.1200/JCO.18.00204.Kluger HM Chiang V Mahajan A Zito CR Sznol M Tran T et al Long-term survival of patients with melanoma with active brain metastases treated with pembrolizumab on a phase II trial J Clin Oncol 2019 37 52 60 10.1200/JCO.18.00204635477230407895Open DOISearch in Google Scholar

21Long GV, Atkinson V, Lo S, Sandhu S, Guminski AD, Brown MP, et al. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol 2018; 19: 672-81. doi: 10.1016/S1470-2045(18)30139-6Long GV Atkinson V Lo S Sandhu S Guminski AD Brown MP et al Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study Lancet Oncol 2018 19 672 81 10.1016/S1470-2045(18)30139-629602646Open DOISearch in Google Scholar

22Tawbi HA, Forsyth PA, Algazi A, Hamid O, Hodi FS, Moschos SJ, et al. Combined nivolumab and ipilimumab in melanoma metastatic to the brain. N Engl J Med 2018; 379: 722-30. doi: 10.1056/NEJMoa1805453Tawbi HA Forsyth PA Algazi A Hamid O Hodi FS Moschos SJ et al Combined nivolumab and ipilimumab in melanoma metastatic to the brain N Engl J Med 2018 379 722 30 10.1056/NEJMoa1805453801100130134131Open DOISearch in Google Scholar